575504-26-6 Usage
Derivative of 1H-inden-4-ol
This means that the compound is a modified version of 1H-inden-4-ol, a naturally occurring organic compound.
Contains a nitro group and a methyl group These functional groups are present in the molecule and contribute to its chemical properties.
Not naturally occurring
This means that the compound is not found in nature and is synthesized in a laboratory.
Used in research and chemical synthesis
This indicates that the compound is mainly used for research purposes and for the synthesis of other chemical compounds.
Pale yellow solid
This describes the physical appearance of the compound.
Potential applications in pharmaceuticals and organic compounds
This suggests that the compound may have potential uses in the development of pharmaceuticals and other organic compounds.
Nitro group makes it a candidate for further chemical modification
The presence of the nitro group makes the compound a good candidate for further chemical modification and synthesis of new compounds with specific properties or functions.
Check Digit Verification of cas no
The CAS Registry Mumber 575504-26-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,5,5,0 and 4 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 575504-26:
(8*5)+(7*7)+(6*5)+(5*5)+(4*0)+(3*4)+(2*2)+(1*6)=166
166 % 10 = 6
So 575504-26-6 is a valid CAS Registry Number.
575504-26-6Relevant articles and documents
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia
Shiohara, Hiroaki,Nakamura, Tetsuya,Kikuchi, Norihiko,Ozawa, Tomonaga,Nagano, Ryuichi,Matsuzawa, Akane,Ohnota, Hideki,Miyamoto, Takahide,Ichikawa, Kazuo,Hashizume, Kiyoshi
experimental part, p. 3622 - 3634 (2012/07/27)
Thyromimetics that specifically target TRβ have been shown to reduce plasma cholesterol levels and avoid atherosclerosis through the promotion of reverse cholesterol transport in an animal model. We designed novel thyromimetics with high receptor (TRβ) and organ (liver) selectivity based on the structure of eprotirome (3) and molecular modeling. We found that indane derivatives are potent and dual-selective thyromimetics expected to avoid hypothyroidism in some tissues as well as heart toxicity. KTA-439 (29), a representative indane derivative, showed the same high human TRβ selectivity in a binding assay as 3 and higher liver selectivity than 3 in a cholesterol-fed rat model.
NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF
-
Page 30, (2010/02/08)
The present invention provides a compound represented by general formula (I): . or pharmaceutically acceptable salts thereof, wherein W is O, S(O)m, CH2 and the like: R1 is halogen, lower alkyl, halo-lower alkyl, CN and th
